Analysts Set Lantheus Holdings, Inc. (NASDAQ:LNTH) Target Price at $85.50

Key Points

• Lantheus Holdings, Inc. has received a consensus recommendation of "Moderate Buy" from analysts, with a target price averaging $85.50.
• Insider sales have significantly impacted share ownership, with individuals selling a total of 6,812,000 shares worth over $382 million in the past three months.
• The company reported quarterly earnings of $1.57 per share, missing estimates and showing a 4.1% decrease in revenue compared to the previous year.

Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) has been given an average rating of "Moderate Buy" by the seven analysts that are covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $85.50.

LNTH has been the subject of a number of research reports. Mizuho decreased their price target on Lantheus from $120.00 to $70.00 and set an "outperform" rating for the company in a research note on Thursday, August 7th. TD Cowen cut their price objective on Lantheus from $95.00 to $80.00 and set a "buy" rating for the company in a report on Monday, September 15th. JMP Securities cut their price objective on Lantheus from $112.00 to $73.00 and set a "market outperform" rating for the company in a report on Thursday, August 7th. B. Riley cut their price objective on Lantheus from $109.00 to $84.00 and set a "buy" rating for the company in a report on Tuesday, September 16th. Finally, William Blair reiterated a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th.

Lantheus Trading Down 2.2%

Shares of NASDAQ:LNTH traded down $1.15 during midday trading on Friday, reaching $50.41. The company's stock had a trading volume of 2,275,969 shares, compared to its average volume of 1,111,426. The firm has a market cap of $3.43 billion, a price-to-earnings ratio of 13.41 and a beta of 0.15. The company has a quick ratio of 4.07, a current ratio of 4.29 and a debt-to-equity ratio of 0.49. Lantheus has a 1 year low of $47.25 and a 1 year high of $118.21. The business has a 50 day moving average price of $60.91 and a 200 day moving average price of $79.59.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The medical equipment provider reported $1.57 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.08). Lantheus had a net margin of 17.82% and a return on equity of 34.06%. The firm had revenue of $378.05 million for the quarter, compared to analysts' expectations of $389.69 million. During the same period last year, the firm posted $1.80 EPS. Lantheus's revenue was down 4.1% on a year-over-year basis. Research analysts forecast that Lantheus will post 6.01 EPS for the current year.

Insider Transactions at Lantheus

In other news, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of the company's stock in a transaction dated Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the sale, the insider directly owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. This represents a 49.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Rajiv A. Patel sold 3,365,000 shares of the stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total transaction of $188,944,750.00. Following the transaction, the insider owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 6,812,000 shares of company stock worth $382,427,380. 2.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On Lantheus

A number of institutional investors have recently added to or reduced their stakes in the company. Peak Retirement Planning Inc. purchased a new stake in shares of Lantheus in the 4th quarter worth about $917,000. Mackenzie Financial Corp increased its stake in Lantheus by 4,907.1% during the 4th quarter. Mackenzie Financial Corp now owns 217,056 shares of the medical equipment provider's stock valued at $19,418,000 after purchasing an additional 212,721 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of Lantheus in the fourth quarter worth approximately $13,081,000. Wealth Enhancement Advisory Services LLC grew its stake in shares of Lantheus by 16.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 4,184 shares of the medical equipment provider's stock worth $374,000 after acquiring an additional 576 shares during the period. Finally, Wellington Management Group LLP purchased a new position in shares of Lantheus in the fourth quarter worth approximately $20,022,000. 99.06% of the stock is owned by institutional investors.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.